Tris-CAR-T is under clinical development by Tasly Pharmaceutical Group and currently in Phase I for Recurrent Glioblastoma Multiforme (GBM). According to GlobalData, Phase I drugs for Recurrent Glioblastoma Multiforme (GBM) have an 87% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Tris-CAR-T’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Tris-CAR-T overview

Tris-CAR-T is under development for the treatment of recurrent glioblastoma. It is administered through Intratumor route. The therapeutic candidate comprises of autologous peripheral blood T cells lentivirally transduced to express a dual-target, truncated IL7Ra modified chimeric antigen receptor (CAR) and acts against cells expressing CD133 and CD44.

Tasly Pharmaceutical Group overview

Tasly Pharmaceutical Group (Tasly) manufactures and distributes chemical medicine, biological medicine, healthcare products, traditional Chinese medicine (TCM), functional food and other products. The company’s product line includes herbal medicine, chemical medicine, prescription drugs, pharmaceutical substances, health product, active pharmaceutical ingredients (APIs), herbal extract, tea, cosmetics, daily hygiene product series, and medical equipment. It markets products in the domestic market through its own sales force and through distributors and subsidiaries in Malaysia, Indonesia, Vietnam, South Korea, Pakistan, Thailand, Istanbul, Botswana, South Africa, Ghana, Kenya, Zambia, Nigeria, Russia, the Netherlands, and the US. Tasly is headquartered in Tianjin, China.

For a complete picture of Tris-CAR-T’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.